Menù principale
B021423 -
Main information
Teaching Language
Course Content
Suggested readings
Learning Objectives
Prerequisites
Teaching Methods
Type of Assessment
Course program
Academic Year 2016-17
Course year
Third year - Annualità singola
Belonging Department
Experimantal and Clinical Medicine
Course Type
Single education field course
Scientific Area
-
Credits
3
Teaching Hours
24
Teaching Term
26/09/2016 ⇒ 30/04/2018
Attendance required
No
Type of Evaluation
Giudizio Finale
Course Content
show
Course program
show
Lectureship
Teaching Language
PROF. ROVIGATTI'S LECTURES ON GENE EXPRESSION CONTROL IN CANCER CELLS AND CELLS FROM CATASTROPHIC HUMAN PATHOLOGIES
Course Content
LECTURE 1. (DECEMBER 12TH)
General Structure and Backbone of our theoretical Understanding of Cancer.
LECTURE 2. (DECEMBER 19TH)
Chromosomal Aberrations and Epigenetic control in Cancer Cells.
LECTURE 3. (DECEMBER 20TH)
Genetic Expression in Malignant Cells. Antibodies, Immune System and their Manipulations for Cancer Immunotherapies (CITs)
LECTURE 4. (DECEMBER 21STH)
Cancer Genomics and Genomics of Catastrophic Monogenic Human Diseases.
General Structure and Backbone of our theoretical Understanding of Cancer.
LECTURE 2. (DECEMBER 19TH)
Chromosomal Aberrations and Epigenetic control in Cancer Cells.
LECTURE 3. (DECEMBER 20TH)
Genetic Expression in Malignant Cells. Antibodies, Immune System and their Manipulations for Cancer Immunotherapies (CITs)
LECTURE 4. (DECEMBER 21STH)
Cancer Genomics and Genomics of Catastrophic Monogenic Human Diseases.
Suggested readings (Search our library's catalogue)
Watson, JD; Caudy AA; Myers RM, Witkowski JA Recombinant DNA, 3rd Edition (WH Freeman and Company). Preferably in the English Edition (i.e., there are some mistakes in the Italian translation) or Translated into Italian by Zanichelli.
Rovigatti, U. (2015). "Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling." Critical Reviews in Oncology/Hematology 96(2): 274-307.
Rovigatti (2016). "The long Journey of Cancer Modeling: Ubi Sumus ? Quo Vadimus ?" Journal of Cancer Science 1(1): 001.
Rovigatti, U. (2015). "Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling." Critical Reviews in Oncology/Hematology 96(2): 274-307.
Rovigatti (2016). "The long Journey of Cancer Modeling: Ubi Sumus ? Quo Vadimus ?" Journal of Cancer Science 1(1): 001.
Learning Objectives
Students will be guided toward an understanding of Recombinant-DNA technologies (especially for gene and protein-expression control) employed in Cancer, for its diagnosis, therapeutic interventions and prognostic evaluation.
Prerequisites
none
Teaching Methods
classroom lessons
Type of Assessment
writing test
Course program
PROF.ROVIGATTI’S LECTURES ON GENE AND PROTEIN EPRESSION MANIPULATION IN CANCER CELLS AND CELLS FROM CATASTROPHIC HUMAN PATHOLOGIES.
LECTURE 1. (MONDAY DECEMBER 12TH à 10.00-13.30)
General structure of our theoretical understanding of the Cancer problem. Oncogenic Viruses, Oncogenes, Tumor Suppressor Genes, Cancer-susceptibility Genes, etc. Actual or planned cancer-gene expression manipulations.
LECTURE 2. (MONDAY DECEMBER 19TH à 10.00-13.30)
Gene expression and its control in normal and malignant (transformed) cells. Paradigm of chromosomal translocations and additional genetic/genomic aberrations. Micro-Arrays technologies (RNA, DNA, proteins etc.). Malignant cells gene expression manipulations. Possible direct therapeutic interventions on transcriptional apparatus.
LECTURE 3. (TUESDAY DECEMBER 20TH à 10.00-13.30)
Epigenetics of cancer cells. RNAi amd miRNA discovery: their actual and potential importance for diagnosis, prognosis and therapeutical approaches to cancer. Few examples of epigenetic or miRNA manipulations in cancer cells. Evolution of theories on antibodies structure and ontogeny: instructive hypothesis (Landsteiner, Haurowitz and Pauling) and clonal selection hypothesis and theory (Ehrlich, Jerne, Burnet and Tonegawa). Fundamental experiments of S. Tonegawa and Shatz and Baltimore. Concept and examples of Targeted Gene Therapy (TGT). Genetic and pharmacological intervention in STP. Cancer Immunotherapies (CITs) only can be long-lasting.
LECTURE 4. (WEDNESDAY DECEMBER 21ST à 10.00-13.30)
Genomics of Cancer and Catastrophic Human Pathologies: From R. Dulbecco’s letter in Science to the Human Genome Project (HGP) and Projects for sequencing malignant cells from several (initially 50) human cancer types (CGP, TCGA, etc.). Importance of genomic mapping and analysis. Examples: NF-1, HD, DMD, CF, FMR-1 etc. Gene-expression manipulation interventions, in order to completely or partially correct such pathologies. New technologies high-through-put and NGS. Concepts of “Precision-Medicine” and “Precision-Oncology” : their biases and failures. Which Landscapes are emerging from human cancer genome studies and how they will influence our therapeutic interventions (also but not only by gene-expression manipulations).
TEXTBOOK: Watson, JD; Caudy AA; Myers RM, Witkowski JA Recombinant DNA, 3rd Edition (WH Freeman and Company) Trad. Zanichelli
ADDITIONAL ARTICLES:
Rovigatti (2016). "The long Journey of Cancer Modeling: Ubi Sumus ? Quo Vadimus ?" Journal of Cancer Science 1(1): 001.
Rovigatti, U. (2015). "Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling." Critical Reviews in Oncology/Hematology 96(2): 274-307.
LECTURE 1. (MONDAY DECEMBER 12TH à 10.00-13.30)
General structure of our theoretical understanding of the Cancer problem. Oncogenic Viruses, Oncogenes, Tumor Suppressor Genes, Cancer-susceptibility Genes, etc. Actual or planned cancer-gene expression manipulations.
LECTURE 2. (MONDAY DECEMBER 19TH à 10.00-13.30)
Gene expression and its control in normal and malignant (transformed) cells. Paradigm of chromosomal translocations and additional genetic/genomic aberrations. Micro-Arrays technologies (RNA, DNA, proteins etc.). Malignant cells gene expression manipulations. Possible direct therapeutic interventions on transcriptional apparatus.
LECTURE 3. (TUESDAY DECEMBER 20TH à 10.00-13.30)
Epigenetics of cancer cells. RNAi amd miRNA discovery: their actual and potential importance for diagnosis, prognosis and therapeutical approaches to cancer. Few examples of epigenetic or miRNA manipulations in cancer cells. Evolution of theories on antibodies structure and ontogeny: instructive hypothesis (Landsteiner, Haurowitz and Pauling) and clonal selection hypothesis and theory (Ehrlich, Jerne, Burnet and Tonegawa). Fundamental experiments of S. Tonegawa and Shatz and Baltimore. Concept and examples of Targeted Gene Therapy (TGT). Genetic and pharmacological intervention in STP. Cancer Immunotherapies (CITs) only can be long-lasting.
LECTURE 4. (WEDNESDAY DECEMBER 21ST à 10.00-13.30)
Genomics of Cancer and Catastrophic Human Pathologies: From R. Dulbecco’s letter in Science to the Human Genome Project (HGP) and Projects for sequencing malignant cells from several (initially 50) human cancer types (CGP, TCGA, etc.). Importance of genomic mapping and analysis. Examples: NF-1, HD, DMD, CF, FMR-1 etc. Gene-expression manipulation interventions, in order to completely or partially correct such pathologies. New technologies high-through-put and NGS. Concepts of “Precision-Medicine” and “Precision-Oncology” : their biases and failures. Which Landscapes are emerging from human cancer genome studies and how they will influence our therapeutic interventions (also but not only by gene-expression manipulations).
TEXTBOOK: Watson, JD; Caudy AA; Myers RM, Witkowski JA Recombinant DNA, 3rd Edition (WH Freeman and Company) Trad. Zanichelli
ADDITIONAL ARTICLES:
Rovigatti (2016). "The long Journey of Cancer Modeling: Ubi Sumus ? Quo Vadimus ?" Journal of Cancer Science 1(1): 001.
Rovigatti, U. (2015). "Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling." Critical Reviews in Oncology/Hematology 96(2): 274-307.